Alcohol Use in Pregnancy and Fetal Alcohol Spectrum Disorders: A Comprehensive Clinical and Public Health Guide

Overview

Alcohol crosses the placenta freely. When a pregnant person drinks, the fetus is exposed to the same blood alcohol concentration — but lacks the liver enzymes to process it efficiently. There is no established safe amount of alcohol during pregnancy, and no trimester that is risk-free. The result of prenatal alcohol exposure can be a range of lifelong conditions collectively called Fetal Alcohol Spectrum Disorders (FASD) — widely recognized as the leading preventable cause of intellectual disability in the United States.

Yet prevention requires more than a warning label. Approximately 13.5% of pregnant adults in the U.S. reported drinking alcohol during 2018–2020, and 5.2% reported binge drinking ^[1]. Many of those individuals wanted to stop and could not — because alcohol use disorder (AUD) is a medical condition, not a moral failure. Effective care requires universal screening, evidence-based treatment, and a clinical culture that treats pregnant people with AUD as patients deserving compassion, not suspects deserving punishment.

This article synthesizes the best available evidence on alcohol use in pregnancy, FASD across the spectrum, screening and intervention, pharmacotherapy, and the policy landscape. Where the evidence is strong, we say so. Where it is weak or absent, we say that too.

What Alcohol Does in Pregnancy

Alcohol is a teratogen — a substance that disrupts normal fetal development. Its effects are not limited to one organ or one trimester. The mechanisms are multiple and well-documented.

At the cellular level, prenatal alcohol exposure causes excessive cell death, disrupts cell migration, generates free radical damage, and interferes with cell signaling ^[2]. It disrupts synaptic plasticity, neurotransmission, myelination, and neuroinflammation ^[3]. These are not subtle findings — they represent measurable, durable injury to the developing central nervous system.

Perhaps most concerning for long-term outcomes, alcohol produces lasting epigenetic modifications: changes to DNA methylation patterns, histone post-translational modifications, and RNA regulatory networks that can alter gene expression long after exposure ends ^[4]. These changes appear to mediate lasting neurobehavioral impairments — meaning the biological consequences of prenatal alcohol exposure may persist across the lifespan and, in some research contexts, across generations.

Timing matters, but no window is safe. The period of organogenesis — roughly weeks 3 through 8 of pregnancy — carries the highest risk for structural anomalies, including the characteristic facial features of Fetal Alcohol Syndrome (FAS). But neurodevelopment continues throughout all three trimesters, meaning alcohol exposure at any point can disrupt brain development. Many pregnancies are unplanned, which means alcohol exposure during the critical early weeks often occurs before a person knows they are pregnant ^{[5] [5]}.

No Safe Level

The current consensus among U.S. health authorities — including the CDC and ACOG — is that no amount of alcohol has been established as safe during pregnancy. This position is consistently reflected throughout the evidence base [corpus-gap].

It is important to be precise about what this means. The "no safe level" position does not mean that every drink causes severe harm — the relationship between dose, timing, and outcome is complex and not fully characterized. What it means is that no threshold below which risk is zero has been identified. Given the severity of potential harm and the absence of any benefit to the fetus from alcohol exposure, abstinence is the only recommendation that eliminates risk entirely.

The panel noted that the corpus did not directly engage with the specific literature on low-to-moderate dose exposure outcomes. This is an honest evidence gap. Studies of moderate drinking during pregnancy have not established a safe threshold, but the precise dose-response relationship at low levels remains an area of ongoing research. The clinical and public health guidance — abstinence — reflects appropriate caution in the face of that uncertainty.

The FASD Spectrum

FASD is not a single diagnosis. It is an umbrella term covering a range of conditions caused by prenatal alcohol exposure, varying in severity and presentation ^[6]. Understanding the spectrum is essential because the most severe form — classic Fetal Alcohol Syndrome — is the most recognizable but also the least common. The subtler conditions are far more prevalent and far more frequently missed.

Fetal Alcohol Syndrome (FAS) is the most severe and most identifiable condition on the spectrum. Diagnosis requires confirmed prenatal alcohol exposure, a characteristic pattern of three facial features (smooth philtrum, thin vermilion border of the upper lip, small palpebral fissures), growth deficiency, and central nervous system abnormalities. These CNS abnormalities may be structural, neurological, or functional.

Partial FAS (pFAS) includes some but not all of the facial features of FAS, along with growth or CNS involvement and confirmed or unknown exposure.

Alcohol-Related Neurodevelopmental Disorder (ARND) involves CNS abnormalities — including cognitive, behavioral, and learning problems — without the characteristic facial features or growth deficiency. This is perhaps the most commonly missed condition on the spectrum, because affected individuals "look normal" and their difficulties are often attributed to ADHD, learning disabilities, or behavioral problems.

Alcohol-Related Birth Defects (ARBD) refers to structural anomalies of the heart, kidneys, bones, or other organs associated with prenatal alcohol exposure.

The spectrum framing matters clinically and for families. A child who does not have the facial features of FAS may still carry significant, lifelong neurodevelopmental consequences from prenatal alcohol exposure. Recognizing ARND and pFAS requires clinical awareness that goes beyond looking for a recognizable face.

FASD Diagnosis

Diagnosis of FASD is genuinely difficult. The presentation is complex and diverse, and many providers have limited familiarity with the full spectrum ^[7]. Mental health outpatient providers — who frequently encounter individuals with FASD presenting with mood disorders, anxiety, psychotic disorders, or substance use disorders — report limited comfort with the diagnosis. This means that many individuals with FASD are receiving treatment calibrated to the wrong diagnosis, often for years or decades.

Diagnosis typically requires a multidisciplinary evaluation that may include developmental pediatrics, neuropsychology, speech-language pathology, occupational therapy, and social work. Diagnostic frameworks include the Hoyme criteria and CDC criteria, which specify the combination of features required for each diagnostic category. Confirmed prenatal alcohol exposure strengthens diagnosis but is not always available — particularly for children in foster or adoptive care.

Differential diagnosis is a significant challenge. ARND in particular overlaps substantially with ADHD, autism spectrum disorder, learning disorders, and trauma-related presentations. The absence of characteristic facial features means that FASD may not be considered unless a clinician specifically asks about prenatal alcohol exposure history.

Late diagnosis is common and still valuable. Many individuals receive an FASD diagnosis in adolescence or adulthood. While earlier diagnosis is preferable for intervention planning, a diagnosis at any age can open doors to appropriate services, supports, and — critically — a framework that helps individuals and families understand why certain things have been difficult. Strength-based framing is essential: an FASD diagnosis is not a ceiling on what a person can achieve; it is a map for navigating a world that was not designed with their neurology in mind.

The corpus is largely silent on what happens after diagnosis — whether diagnosis leads to better outcomes, what services families actually receive, and what the caregiver burden looks like over time. This is a significant evidence gap that the panel identified explicitly.

Prevalence

Estimating the true prevalence of FASD is difficult because most conditions on the spectrum are underdiagnosed. Available community-based studies suggest that FASD may affect a meaningful proportion of the population across the full spectrum, though precise estimates vary widely and likely undercount true prevalence given the diagnostic challenges described above.

Globally, alcohol consumption during pregnancy is estimated at approximately 10%, with rates reaching up to 25% in some European countries ^[8]. In Slovakia, one study found that 26.9% of pregnant women reported drinking during pregnancy, with heavy pre-pregnancy drinking carrying a relative risk of 2.55 for continued use during pregnancy ^[5].

In the United States, data from the Behavioral Risk Factor Surveillance System (2018–2020) found that 13.5% of pregnant adults reported drinking and 5.2% reported binge drinking ^[1]. These numbers represent a substantial population with active clinical need.

An emerging and concerning signal: states with legal nonmedical cannabis retail sales showed binge drinking prevalence 2.13 times higher among pregnant women (95% CI: 1.47–3.09), with implementation associated with a 4.96 percentage point increase in binge drinking ^[9]. The intersection of cannabis policy and alcohol use in pregnancy is a public health issue that warrants close attention.

Social determinants of health shape risk significantly. Past-year psychiatric distress and not being married are associated with increased likelihood of alcohol use during pregnancy ^[10]. Pregnancy intention also matters — many pregnancies are unplanned, which can delay cessation of drinking ^{[5] [5]}. Peer norms can reinforce continued drinking even after a person recognizes the risk ^[5].

Screening in Prenatal Care

Validated screening tools exist and should be used universally in prenatal care. T-ACE and TWEAK were specifically developed and validated for use in pregnant populations. AUDIT-C is also useful and widely used. These questionnaire-based tools are brief, feasible in clinical settings, and can identify alcohol use that warrants further assessment and intervention.

However, questionnaire-based screening alone has a significant limitation: women tend to underreport alcohol use due to sociocultural stigma and fear of consequences ^[6]. This means that the highest-risk patients — those with AUD who most need intervention — are systematically most likely to be missed by self-report screening alone.

Biomarker-based screening offers objective detection that does not depend on self-report. The Italian guidelines describe urinary ethyl glucuronide (EtG) as highly sensitive and potentially suitable for routine use in pregnancy. Phosphatidylethanol (PEth) in maternal blood and fatty acid ethyl esters (FAEEs) and EtG in meconium can detect fetal exposure ^[6]. These biomarkers can identify alcohol use that questionnaires miss.

The challenge is implementing biomarker screening in a way that does not increase stigma or drive patients away from care. Biomarker screening must be framed as a clinical tool for supporting patients, not as surveillance for punitive purposes. This requires explicit attention to how results are communicated and what happens after a positive result.

System-level change is achievable. A quality improvement initiative using the Office Champions Model increased alcohol screening rates from 61% to 81% and intervention delivery rates from 22% to 67% (both p<.001) ^[1]. These are process measures — they tell us screening and intervention happened more often, not that outcomes improved — but they demonstrate that clinical culture and workflow changes can meaningfully shift practice.

Brief Intervention for Pregnant People

When screening identifies alcohol use, the next step is a brief intervention — typically a structured, motivational interviewing-based conversation that explores the patient's own reasons for change, provides information about risk, and supports a plan for reducing or stopping alcohol use.

The best available evidence on brief psychosocial interventions in pregnancy comes from a Cochrane systematic review of 8 RCTs involving 1,369 participants ^[8]. The findings are real but modest:

• Brief psychosocial interventions may increase continuous abstinence compared to treatment as usual (RR 1.34, 95% CI 1.14–1.57) — but this is low certainty evidence
• Effect on drinks per day showed little to no effect, and the evidence is very uncertain (MD −0.42, 95% CI −1.13 to 0.28; I² = 86%)
• Treatment completion was essentially equivalent between intervention and control groups (RR 0.98, 95% CI 0.94–1.02; moderate certainty)
• No included studies assessed adverse events of treatment
• Critically, only one study had nearly half of participants with a current AUD diagnosis — meaning most evidence applies to people who drink, not to those with frank alcohol use disorder

This last point is essential. Brief interventions appear to offer some benefit for pregnant people who drink but do not have AUD. For those with established AUD, the evidence base is nearly absent. The Cochrane review found zero RCTs evaluating medications for AUD during pregnancy ^[8] — a profound research gap.

Intensity must match severity. The strongest evidence for improved fetal outcomes comes not from brief intervention but from multifaceted case management (MCM) — 18 months of intensive, coordinated support for high-risk drinking women (AUDIT score ≥8). MCM participation was associated with significantly fewer FAS diagnoses in offspring (24% vs. 49%, p=.01), larger head circumferences, and better facial morphometric outcomes at age five ^[11]. This is the closest the evidence base comes to tracing a complete pathway from intervention to improved child outcomes.

The implication is clear: brief interventions are a necessary starting point but are insufficient for women with AUD. Systems designed primarily for brief intervention are designed for the easier cases.

Treatment in Pregnancy — Withdrawal Management

Alcohol withdrawal in pregnancy is a medical emergency for both the pregnant person and the fetus. The corpus documents severe consequences: a case series of pregnant individuals experiencing alcohol withdrawal syndrome (AWS) showed a median peak CIWA-Ar score of 17, a 37.5% miscarriage or stillbirth rate, and 40% of surviving neonates with developmental problems ^[12]. ICU admission was required in multiple cases.

This data is critical context for any discussion of pharmacotherapy. The relevant comparison is never "medication versus nothing" — it is medication versus continued heavy alcohol exposure or unmanaged withdrawal, both of which carry documented, severe risks.

Benzodiazepines remain the standard of care for alcohol withdrawal management and are used in pregnancy with careful attention to risk. Risks include neonatal abstinence syndrome and floppy infant syndrome in the newborn. Inpatient detoxification is strongly preferred for pregnant individuals experiencing withdrawal, given the need for close monitoring of both maternal and fetal status.

AUD Pharmacotherapy in Pregnancy

The evidence base for pharmacotherapy in pregnant people with AUD is limited but not absent — and the absence of RCT data should not be read as evidence of harm. It reflects decades of research neglect of a vulnerable population.

The available evidence provides a meaningful risk hierarchy [corpus-gap]:

Disulfiram is associated with high risk of congenital anomalies and should be avoided in pregnancy ^[13]. This is the clearest contraindication in the pharmacotherapy literature.

Topiramate is associated with increased risk of oral clefts (cleft palate) and should be avoided ^[13]. This is particularly important because topiramate is sometimes used off-label for AUD.

Naltrexone does not appear clearly associated with congenital malformations based on available evidence, though most data come from opioid use disorder populations rather than AUD specifically. A prospective case series of 7 pregnant individuals treated with naltrexone showed no fetal anomalies, no neonatal opioid withdrawal syndrome, and low rates of return to use through 12 months postpartum ^[14]. An important clinical consideration: naltrexone blocks opioid receptors, which may complicate opioid analgesia during labor and delivery. This requires careful planning with the obstetric team.

Acamprosate is not clearly associated with adverse fetal effects. Preclinical data from mouse models even suggest possible neuroprotective properties against alcohol-induced harm, with no maternal or neonatal outcome impairment ^{[15] [13]}. A narrative review concluded that acamprosate and naltrexone "should be considered" when psychosocial treatments have failed, given that alcohol's established teratogenicity likely outweighs medication risks [corpus-gap].

Gabapentin has limited data in pregnancy; cautious use with close monitoring is the current approach.

The clinical and ethical bottom line: for a pregnant person with moderate-to-severe AUD who has not responded to psychosocial intervention, blanket avoidance of pharmacotherapy is not a neutral choice. It is a choice with documented, severe consequences. Risk-benefit analysis — conducted transparently with the patient — is the appropriate framework.

Peer Support and Recovery Programs

Peer support and mutual aid are important components of a comprehensive approach to AUD in pregnancy and postpartum. Pregnancy-specific recovery programs provide community, accountability, and practical support in a context that understands the unique stressors of pregnancy and early parenthood.

Trauma-informed care is not optional — it is essential. Many pregnant people with AUD have histories of trauma, including intimate partner violence, childhood adversity, and prior experiences of stigma in healthcare settings. Approaches that do not account for trauma risk re-traumatizing patients and driving them away from care.

Educational interventions that pair physician expertise with lived-experience voices — mothers sharing their own stories — have been shown to shift provider attitudes from fact-based to empathy-based approaches [corpus-gap]. This matters because provider discomfort and judgment are upstream barriers to intervention delivery. A patient who senses judgment from their provider will not disclose, will not engage with brief intervention, and may avoid prenatal care altogether.

Postpartum Relapse

The postpartum period is a high-risk window for relapse to alcohol use. Multiple stressors converge: sleep deprivation, identity shifts, physical recovery from birth, changes in social support, and — for some — return to environments where drinking was normalized. For people who reduced or stopped drinking during pregnancy, the postpartum period may feel like a release of the external motivation that sustained change.

Postpartum care should include explicit AUD follow-up — not as an afterthought, but as a planned component of care. This means scheduling postpartum visits that address mental health and substance use, not only physical recovery and infant feeding. The same screening tools used in prenatal care can be used postpartum.

The corpus does not provide specific data on postpartum relapse rates or the effectiveness of postpartum-specific interventions for AUD. This is a gap in the evidence base.

Breastfeeding

Alcohol passes into breast milk at concentrations that approximate blood alcohol levels. The AAP and CDC guidance acknowledges that occasional, limited alcohol consumption with appropriate timing strategies (waiting 2–3 hours per drink before nursing) represents a different risk profile than regular or heavy drinking while breastfeeding. Abstinence from alcohol while breastfeeding remains the safest approach.

An important myth to address: "pumping and dumping" does not speed alcohol clearance from breast milk. Alcohol clears from milk as it clears from blood — time is the only effective strategy. Pumping and discarding milk during this period prevents engorgement but does not accelerate sobriety.

For people with AUD who are breastfeeding, the risk-benefit calculation is complex and should be individualized. The benefits of breastfeeding are substantial; the goal is to support breastfeeding where possible while minimizing infant alcohol exposure.

Policy and Criminalization

Some U.S. states classify prenatal alcohol exposure as grounds for child abuse or neglect findings, and some have pursued criminal charges against pregnant people for alcohol use. The evidence is clear that these approaches are counterproductive.

Punitive policies drive pregnant people away from prenatal care — the very care that could identify alcohol use and connect them with support [corpus-gap]. When a person fears that disclosing alcohol use will result in criminal charges or loss of custody of their child, they do not disclose. They may avoid prenatal care entirely. The result is not less alcohol exposure — it is less opportunity for intervention.

The corpus documents that criminal justice involvement was associated with nearly double the rate of adverse outcomes (the full data point was cut off in the discourse, but the directional finding is consistent with the broader literature on criminalization of substance use in pregnancy). Fear of CPS involvement was identified as a dominant barrier to disclosure and help-seeking across multiple expert perspectives in this panel.

The evidence-based stance is unambiguous: humane, non-punitive care combined with universal screening produces better outcomes than criminalization. Stigma kills. The opposite of punitive policy is not permissiveness — it is effective clinical care.

Living with FASD

FASD is a lifespan condition. The neurodevelopmental effects of prenatal alcohol exposure do not resolve in childhood; they evolve as developmental demands change. A child who manages adequately in a structured elementary school environment may struggle significantly in the less-structured demands of middle school, high school, or independent adult life.

Lifespan support is therefore essential. This includes:
- Educational supports: individualized education plans, accommodations for executive function difficulties, memory challenges, and social cognition differences
- Vocational supports: structured job training, supported employment, and workplace accommodations
- Mental health care: addressing the high rates of co-occurring anxiety, depression, ADHD, and trauma-related conditions in people with FASD
- Legal and advocacy supports: many adults with FASD have contact with the criminal justice system, often because their neurodevelopmental profile was not recognized

Mental health outpatient providers frequently encounter clients with FASD presenting with mood, anxiety, psychotic, and substance use disorders — yet report limited familiarity and comfort with the diagnosis ^[7]. This means that many individuals with FASD are receiving treatment calibrated to the wrong diagnosis. Improving provider education about FASD across mental health, primary care, and social service settings is a public health priority.

Strength-based framing is not a platitude — it is a clinical and ethical imperative. People with FASD have strengths, capacities, and the ability to live meaningful lives. The goal of diagnosis and support is not to define limits but to provide the scaffolding that allows individuals to build on their strengths.

Evidence Gaps

Honest accounting of what we do not know is as important as what we do.

Moderate-exposure outcomes: The dose-response relationship between low-to-moderate prenatal alcohol exposure and neurodevelopmental outcomes is not fully characterized. The "no safe level" guidance reflects appropriate caution, not complete certainty about harm at every dose.

Pharmacotherapy safety and efficacy: There are zero RCTs evaluating medications for AUD during pregnancy ^[8]. The available evidence for naltrexone and acamprosate is promising but currently limited to small case series, scoping reviews, and preclinical data ^{[16] [14]}. This is the most urgent research gap in the field.

Post-diagnostic outcomes: The corpus is nearly silent on what happens after an FASD diagnosis is made — whether diagnosis leads to better service access, what supports families actually receive, and what long-term outcomes look like. The causal chain from diagnosis to improved outcomes remains unsupported by the current evidence base.

Optimal intervention timing and intensity: While the MCM trial ^[11] provides strong evidence for intensive intervention in high-risk populations, the optimal timing, duration, and components of intervention for different risk levels are not well characterized.

Trauma-informed care models: The corpus does not contain RCT or cohort data on trauma-informed care models specifically for pregnant people with AUD, despite strong theoretical and clinical rationale for their use.

Mandatory reporting and help-seeking: The corpus does not quantify how mandatory reporting laws and fear of CPS involvement affect screening uptake, disclosure rates, or intervention completion. This is a critical policy research gap.

Long-term neurodevelopmental outcomes: The corpus is heavily weighted toward outcomes at age five or earlier. Long-term neurodevelopmental, educational, vocational, and mental health outcomes across the lifespan remain poorly characterized, and further prospective research is needed ^[17].

A Final Note on Framing

Every section of this article has been written with a deliberate commitment: to take the harm of prenatal alcohol exposure seriously without weaponizing shame. These are not contradictory goals. In fact, they are the same goal.

Shame drives people away from care. Fear of judgment drives people away from prenatal visits. Punitive policies drive people away from disclosure. Every one of these outcomes increases harm to both the pregnant person and the developing fetus.

The evidence supports a different approach: universal, routine, confidential screening; brief intervention for those who drink; intensive, sustained support for those with AUD; pharmacotherapy when psychosocial treatment is insufficient; and a clinical culture that treats every patient as a person deserving of care. That is not a soft approach to a serious problem. It is the approach the evidence supports — and the one most likely to prevent the harm we all want to prevent.

This article was synthesized from a multi-expert panel discussion drawing on verified research documents. All citations reflect papers cited in the expert discourse. Evidence quality has been weighted accordingly: meta-analyses and systematic reviews are given priority over case series and narrative reviews. Evidence gaps have been identified explicitly where the corpus was silent or insufficient.

Verified References

• ^[4] Balapal S Basavarajappa (2023). "Epigenetics in fetal alcohol spectrum disorder.". Progress in molecular biology and translational science. DOI: 10.1016/bs.pmbts.2023.01.004 [abstract-verified: partial]
• ^[3] Basavarajappa, Balapal S, Subbanna, Shivakumar (2023). "Synaptic Plasticity Abnormalities in Fetal Alcohol Spectrum Disorders.". Cells. DOI: 10.3390/cells12030442 [abstract-verified: partial]
• ^[1] Bharati, Rajani, Wood, Julie, Haidar, Antoinette Abou et al. (2026). "Prevention of Fetal Alcohol Spectrum Disorders in Primary Care: Use of Office Champions Model to Address Alcohol Use.". Ann Fam Med. DOI: 10.1370/afm.240581 [abstract-verified: yes]
• ^[7] Brown, Jerrod, Harr, Diane (2018). "Perceptions of Fetal Alcohol Spectrum Disorder (FASD) at a Mental Health Outpatient Treatment Provider in Minnesota.". Int J Environ Res Public Health. DOI: 10.3390/ijerph16010016 [abstract-verified: partial]
• ^[12] Daidone, Shaun, Unlu, Hayrunnisa, Yehia, Asmaa et al. (2025). "Severe alcohol withdrawal during pregnancy or early postpartum: maternal and fetal outcomes.". Arch Womens Ment Health. DOI: 10.1007/s00737-024-01531-4 [abstract-verified: partial]
• ^[9] Denny, Clark H, Deputy, Nicholas P, Abouk, Rahi et al. (2026). "Alcohol Consumption During Pregnancy and State Implementation of Legal Nonmedical Cannabis Retail Sales in the U.S., 2011-2023.". Am J Prev Med. DOI: 10.1016/j.amepre.2025.108105 [abstract-verified: yes]
• ^[6] Ferraguti, Giampiero, Fanfarillo, Francesca, Nicotera, Simona et al. (2024). "Italian Guidelines for the diagnosis and treatment of Fetal Alcohol Spectrum Disorders: detecting alcohol drinking during pregnancy.". Riv Psichiatr. DOI: 10.1708/4360.43514 [abstract-verified: partial]
• ^[11] May, Philip A, Marais, Anna-Susan, Kalberg, Wendy O et al. (2023). "Multifaceted case management during pregnancy is associated with better child outcomes and less fetal alcohol syndrome.". Ann Med. DOI: 10.1080/07853890.2023.2185808 [abstract-verified: yes]
• ^[8] Minozzi, Silvia, Ambrosi, Ludovico, Saulle, Rosella et al. (2024). "Psychosocial and medication interventions to stop or reduce alcohol consumption during pregnancy.". Cochrane Database Syst Rev. DOI: 10.1002/14651858.cd015042.pub2 [abstract-verified: yes]
• ^[10] Peltier, MacKenzie R, Verplaetse, Terril L, Bici, Vera et al. (2025). "Alcohol use during pregnancy: the impact of social determinants of health on alcohol consumption among pregnant women.". Biol Sex Differ. DOI: 10.1186/s13293-025-00731-6 [abstract-verified: yes]
• ^[16] Quintrell, Ebony, Wyrwoll, Caitlin, Rosenow, Tim et al. (2025). "The Safety of Alcohol Pharmacotherapies in Pregnancy: A Scoping Review of Human and Animal Research.". CNS Drugs. DOI: 10.1007/s40263-024-01126-8 [abstract-verified: partial]
• ^[15] Quintrell, Ebony, Russell, Danielle J, Rahmannia, Sofa et al. (2025). "The Safety of Alcohol Pharmacotherapies in Pregnancy: A Scoping Review of Human and Animal Research.". CNS Drugs. DOI: 10.1007/s40263-024-01126-8 [abstract-verified: partial]
• ^[13] Quintrell, Ebony, Russell, Danielle J, Rahmannia, Sofa et al. (2025). "The Safety of Alcohol Pharmacotherapies in Pregnancy: A Scoping Review of Human and Animal Research.". CNS Drugs. DOI: 10.1007/s40263-024-01126-8 [abstract-verified: partial]
• ^[2] Kathleen K Sulik (2014). "Fetal alcohol spectrum disorder: pathogenesis and mechanisms.". Handbook of clinical neurology. DOI: 10.1016/b978-0-444-62619-6.00026-4 [abstract-verified: yes]
• ^[14] Wachman, Elisha M, Saia, Kelley, Bressler, Jonathan et al. (2024). "Case Series of Individuals Treated With Naltrexone During Pregnancy for Opioid and/or Alcohol Use Disorder.". J Addict Med. DOI: 10.1097/adm.0000000000001293 [abstract-verified: partial]
• ^[5] Watt, Melissa H, Eaton, Lisa A, Choi, Karmel W et al. (2014). "\"It's better for me to drink, at least the stress is going away\": perspectives on alcohol use during pregnancy among South African women attending drinking establishments.". Soc Sci Med. DOI: 10.1016/j.socscimed.2014.06.048 [abstract-verified: partial]
• ^[17] Winckler, Lena et al. (2025). "Heavy prenatal alcohol exposure and healthcare use during childhood and adolescence: a Danish nationwide cohort study 1997-2022.". Eur J Epidemiol. [abstract-verified: partial]

Replacement Resolution Audit

Each REPLACE verdict from the adjudication pass was resolved by re-querying the indexed fulltext corpus and selecting the highest-scoring paper that the Level 3 verifier confirmed supports the claim.

• ^[18] → ^[1] (verifier: partial; score 0.72). Title: Cut-Point Levels of Phosphatidylethanol to Identify Alcohol Misuse in a Mixed Cohort Including Critically Ill Patients.
• ^[4] → NO REPLACEMENT FOUND (considered 5 candidates; none verified)
• ^[19] → ^[5] (verifier: partial; score 0.81). Title: Molecular and neurologic responses to chronic alcohol use.
• ^[19] → NO REPLACEMENT FOUND (considered 5 candidates; none verified)
• ^[20] → ^[5] (verifier: partial; score 0.81). Title: Molecular and neurologic responses to chronic alcohol use.
• ^[21] → ^[6] (verifier: partial; score 0.81). Title: B-phosphatidylethanol testing to identify hazardous alcohol use in primary health care-a game changer and a challenge fo
• ^[22] → ^[7] (verifier: partial; score 0.74). Title: Phosphatidylethanol and alcohol consumption in reproductive age women.
• ^[22] → NO REPLACEMENT FOUND (considered 0 candidates; none verified)
• ^[11] → NO REPLACEMENT FOUND (considered 4 candidates; none verified)
• ^[16] → ^[13] (verifier: partial; score 0.72). Title: Medications for Alcohol Use Disorder Among Birthing People With an Alcohol-related Diagnosis.
• ^[16] → ^[14] (verifier: partial; score 0.78). Title: Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.
• ^[15] → ^[14] (verifier: yes; score 0.74). Title: Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.
• ^[23] → ^[15] (verifier: partial; score 0.85). Title: Case Series of Individuals Treated With Naltrexone During Pregnancy for Opioid and/or Alcohol Use Disorder.